International Journal of Medical and Dental Sciences

Open Access Open Access  Restricted Access Subscription Access

Assessing Response of Perimenopausal Abnormal Uterine Bleeding after Treatment


Affiliations
1 Department of OBG Government Medical College Anantapuramu - 515001, Andhra Pradesh, India
 

Background:Abnormal Uterine Bleeding (AUB) is caused by either Organic lesions such as genital tract infections, tumors, adenomyosis, pregnancy and its complications, systemic disorders or Dysfunctional Uterine Bleeding (DUB). In women ≥ 40 years, and certainly in menopausal patients, it mandates evaluation to confirm benign nature of the problem, by ruling out endometrial carcinoma, so that medical treatment or conservative surgery can be offered and unnecessary radical surgery can be avoided.

Objectives: Categorizing of Perimenopausal women with AUB for further management according to histo-pathological report and to study the efficacy of medical management (Mainly Progestins).

Material and Methods: A total of 60 patients were selected who presented with symptoms of abnormal uterine bleeding at perimenopausal age group (40-54 years). Histopathological results were evaluated after obtaining endometrial tissue and patients are treated accordingly. Treatment response was assessed and tabulated. Statistical Analysis has done by danielsoper.com using chi-square test.

Results: Abnormal uterine bleeding was mostly seen in multiparous women with parity >2 about 63.3%. Among menstural irregularities, 45% of cases presented with menorrhagia. Most of the patients were diagnosed as Anovulatory DUB about 60%. Out of 11 hyperplasia patients, 2 (18.1%) patients diagnosed as complex hyperplasia without atypia. No progression of AUB has seen after MPA treatment among all patients with endometrial hyperplasia.

Conclusion: Cyclical oral progestogens are effective in regulating and reducing irregular bleeding due to Oligo/Anovulation. Majority of the cases of endometrial hyperplasia without atypia can be successfully treated with progestogen therapy.


User
Notifications
Font Size


  • Campbell S, Monga A. Gynaecology by Ten Teachers. 17th ed. Arnold; 2000.p. 41-54.

  • Bayer SR, DeCherney AH. Clinical Manifestations and Treatment of Dysfunctional Uterine Bleeding. JAMA 1993;269:1823-8.

  • Padubidri VG, Daftary SN. Howkins and Bourne Shaw's Text book of Gynaecology. 14th ed. Noida: Reed Elsevier India Private Limited; 2008.p.52-62.

  • Symonds IM. Establishing outpatient hysteroscopy service. Current Obstet Gynecol 1999;9:158-62.

  • Schorge, Schaffer. Abnormal uterine bleeding. In: Williams Gynaecology. New York: McGraw-Hill; 2008.p.174-96.

  • Sukhbir Singh, Carolyn Best, Sheila Dunn, Nicholas Leyland, Wendy Lynn Wolfman. Abnormal Uterine Bleeding in Pre-Menopausal Women, Journal of Obstetrics and Gynaecology Canada 2013 May;35(5):292.

  • Sajitha K, Shetty K Padma, Jayaprakash Shetty K, Kishan prasad H, Harish S Permi, Panna Hedge. Study of histopathological patterns of endometrium in abnormal uterine bleeding. CHRISMED Journal of Health and Research 2014 Apr-Jun;1(2):76-81.

  • Najeeb R, Awan AS, Bakhtiar U, Akhter S. Role of transvaginal sonography in assessment of abnormal uterine bleeding in perimenopausal age group. J Ayub Med Coll Abbottabad 2010; 22(1):87-90.

  • Rajshri P Damle, Dravid NV, Kishor H Suryawanshi, Arundhati S Gadre, Priya S Bagale, Neelam Ahire.Clinicopathological Spectrum of Endometrial Changes in Perimenopausal and Post-menopausal Abnormal Uterine Bleeding: A 2 Years Study. Journal of Clinical and Diagnostic Research 2013 Dec;7(12):2774-6.

  • Usha G Doddamani, GB Doddamani, Geethanjali Katageri, Ashalata Mallapur. Clinicopathological Correlation of Endometrium in Abnormal Uterine Bleeding. Sch J App Med Sci 2014; 2(1A):46-9.

  • Getpook C, Wattanakumtornkul. Endometrial thickness screening in premenopausal women with abnormal uterine bleeding. J Obstet Gynaecol Res 2006;32(6):588-92.

  • Bhoomika Dadhania, Gauravi Dhruva, Amit Agravat, Krupal Pujara. Histopathological study of endometrium in dysfunctional uterine bleeding. Int J Res Med 2013;2(1);20-4.

  • Fraser IS. Treatment of ovulatory and anovulatory dysfunctional uterine bleeding with oral progestogens. Aust N Z J Obstet Gynaecol 1990;30:353-6.

  • Kriplani A, Singh BM, Lal S, Agarwal N. Efficacy, acceptability and side effects of the levonorgestrol intrauterine system for menorrhagia. J Obstet Gynaecol 2007 Jun;97(3):190-4.

  • Kriplani A, Kulshrestha V, Agarwal N, Diwakar S. Role of Tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. J Obstet Gynaecol 2006 Oct;26(7):673-8.

  • Ayse Kavasoglu Tosun, Ismet Tosun, Necdet Suer. Comparison of levonorgestrol-releasing intrauterine device with oral progestin in heavy menstrual bleeding (HMB) cases with uterine leiomyoma (LNG-IUD and oral progestin usage in myoma uteri). Pak J Med Sci 2014 Jul-Aug;30(4):834-9.

  • Nina Mansukhani, Jyothi Unni, Sonal Bathla. Are women satisfied when using Levonorgestrel-releasing intrauterine system for treatment of abnormal uterine bleeding? J Midlife Health 2013 Jan-Mar;4(1):31-5.

  • Reed SD, Voight LF, Newton KM, Gracia RH, Allison HK, Epplein M et al. Progestin therapy of complex endometrial hyperplasia with and without atypia. Obstet Gynecol 2009 Mar;113(3):655-62.

  • Tasci Y, Polat OG, Ozdogan S, Karcaaltincaba T, Seckin L, Erkaya S. Comparison of the efficacy of micronized progesterone and lynestrenol in treatment of simple endometrial hyperplasia without atypia. Arch Gynecol Obstet 2014;290(1):83-6.

  • Marra C, Penati C, Ferrari L, Cantu MG, Bargossi L, Fruscio R. Treatment of simple and complex endometrial nonatypical hyperplasia with natural progesterone: response rate to different doses. Gynecol Endocrinol 2014 Sep 25;30(12):899-901.

  • Horn LC, Schnurbusch U, Bilek K, Hentschel B, Einenkel J. Risk of progression in complex and atypical endometrial hyperplasia:clinicopathologic analysis incases with and without progestogen treatment. Int J Gynecol Cancer 2004;14:348-53.

  • Simender Mesci-Haftaci, Handan Ankarali, Ali Yavuzcan. Endometrial Curettage in Abnormal Uterine Bleeding and Efficacy of Progestins for Control in Cases of Hyperplasia. Asian Pac J Cancer Prev 2013;15(8):3737-40.

  • Tabata T, Yamawaki T, Yabana T, Ida M, Nishimura K, Nose Y. Natural history of endometrial hyperplasia. Study of 77 patients. Arch Gynecol Obstet 2001;265:85-8.

  • Montgomery BE, Daum GS, Dunton CJ. Endometrial hyperplasia: a review. Obstet Gynecol Surv 2004;59:368-78.

  • Simpson AN, Feigenberg T, Clarke BA, Gien LT, Ismiil N, Laframboise S, Massey C, Ferguson SE. Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin. Gynecol Oncol 2014;133:229-33.


Abstract Views: 262

PDF Views: 126




  • Assessing Response of Perimenopausal Abnormal Uterine Bleeding after Treatment

Abstract Views: 262  |  PDF Views: 126

Authors

M. S. Shobha Rani
Department of OBG Government Medical College Anantapuramu - 515001, Andhra Pradesh, India
M. Mallika
Department of OBG Government Medical College Anantapuramu - 515001, Andhra Pradesh, India

Abstract


Background:Abnormal Uterine Bleeding (AUB) is caused by either Organic lesions such as genital tract infections, tumors, adenomyosis, pregnancy and its complications, systemic disorders or Dysfunctional Uterine Bleeding (DUB). In women ≥ 40 years, and certainly in menopausal patients, it mandates evaluation to confirm benign nature of the problem, by ruling out endometrial carcinoma, so that medical treatment or conservative surgery can be offered and unnecessary radical surgery can be avoided.

Objectives: Categorizing of Perimenopausal women with AUB for further management according to histo-pathological report and to study the efficacy of medical management (Mainly Progestins).

Material and Methods: A total of 60 patients were selected who presented with symptoms of abnormal uterine bleeding at perimenopausal age group (40-54 years). Histopathological results were evaluated after obtaining endometrial tissue and patients are treated accordingly. Treatment response was assessed and tabulated. Statistical Analysis has done by danielsoper.com using chi-square test.

Results: Abnormal uterine bleeding was mostly seen in multiparous women with parity >2 about 63.3%. Among menstural irregularities, 45% of cases presented with menorrhagia. Most of the patients were diagnosed as Anovulatory DUB about 60%. Out of 11 hyperplasia patients, 2 (18.1%) patients diagnosed as complex hyperplasia without atypia. No progression of AUB has seen after MPA treatment among all patients with endometrial hyperplasia.

Conclusion: Cyclical oral progestogens are effective in regulating and reducing irregular bleeding due to Oligo/Anovulation. Majority of the cases of endometrial hyperplasia without atypia can be successfully treated with progestogen therapy.


References





DOI: https://doi.org/10.18311/ijmds%2F2016%2F100599